Summary of Key Points from Conference Call Company Overview - The company discussed is **必贝特 (Bebetter)**, which focuses on innovative drug development, particularly in the field of RNA therapeutics. Industry Insights - The approval of **PCSK9/AGT dual-target siRNA** for Phase 1/2 IND in China marks a significant milestone in the treatment of **mild to moderate hypertension** combined with elevated **low-density lipoprotein cholesterol (LDL-C)** [1] - The global market for hypertension patients is approximately **1.4 billion**, with **245 million** patients in China, indicating a substantial market opportunity [1] Core Developments - The company utilizes a proprietary **GDOC technology platform** that features a unique parallel structural design, which is expected to enhance the stability and delivery efficacy of the siRNA [1] - The dual-target approach is positioned to provide synergistic benefits in lowering blood pressure and cholesterol, potentially improving patient adherence to medication regimens [1] Pipeline Highlights - The company has several projects in its pipeline, including: - **BEBT-507** for **TMPRSS6** in polycythemia vera (Phase 1) - **BEBT-701** targeting **AGT + PCSK9** for hypertension and hyperlipidemia - **BEBT-706** for **Lp(a) + PCSK9** in atherosclerotic cardiovascular disease (ACSVD) - **BEBT-720** for **CIDEB + HSD17B13** in metabolic-associated steatotic liver disease (MASH) - **BEBT-758** targeting **SNCA** for Parkinson's disease - **BEBT-756** for **APP + Tau** in Alzheimer's disease - Additional projects addressing **hyperuricemia and gout**, **renal anemia/CKD**, and **diabetes** [2][3] Strategic Recommendations - Continued focus on the dual-target project and advancements in **CNS-targeted delivery** and **renal delivery** systems is recommended for potential breakthroughs in treatment [2]

Core Insights - The company is strategically expanding into the small RNA platform to address age-related chronic diseases, aiming to develop a pipeline with long-term value and transition into a Pharma company [1][2]. Group 1: Company Overview - The company has established a partnership with AditumBio to form KalexoBio, focusing on a dual-target siRNA drug, 2MW7141, for cardiovascular diseases, with a total deal value of $1 billion [2]. - The company has a strong asset management background, with the fund managing assets of 16.182 billion yuan and achieving a one-year return of 54.74% for its best-performing fund [1]. Group 2: Product Development - The dual-target siRNA drug 2MW7141 is designed to address unmet clinical needs in cardiovascular treatment, with preliminary data showing strong efficacy in animal models [3][5]. - The siRNA technology platform emphasizes differentiated innovation, utilizing AI for automated design and screening, and optimizing delivery methods for both liver-targeted and extrahepatic applications [4]. Group 3: Research and Clinical Trials - The α-synuclein-targeting PET tracer [18F]-FD4 has received funding from the Michael J. Fox Foundation to accelerate its development for Parkinson's disease and related disorders, with potential for early diagnosis and monitoring [6][7]. - The company is advancing multiple clinical pipelines, including 9MW2821 for bladder cancer and 9MW1911 for COPD, with significant milestones expected in the coming years [8][9].